Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP).
Linong Ji, Weihong Song, Hui Fang, Wei Li, Jianlin Geng, Yangang Wang, Lian Guo, Hanqing Cai, Tao Yang, Hongmei Li, Gangyi Yang, Qifu Li, Kuanzhi Liu, Shuying Li, Yanjun Liu, Fuyan Shi, Xinsheng Li, Xin Gao, Haoming Tian, Qiuhe Ji, Qing Su, Zhiguang Zhou, Wenbo Wang, Zunhai Zhou, Xuejun Li, Yancheng Xu, Zhiqiang Ning, Haixiang Cao, Desi Pan, He Yao, Xianping Lu, Weiping Jia
Science bulletin 2023;66(15):1571-1580